Our univariate analysis has revealed that lung cancer patients (p-stages I to IV) carrying homozygous SNP alleles (–617A/A) in the NRF2 gene experienced significantly better overall survival, as compared with patients with heterozygous alleles (c.–617C/A) (log-rank P = 0.021). The gene discussed is NFE2L2; the disease is lung carcinoma.